Log in with your email address username.


[Correspondence] Inhaled triple therapy in chronic obstructive pulmonary disease

Single-inhaler triple therapy has been proposed for patients with symptomatic, frequently exacerbating chronic obstructive pulmonary disease (COPD), with the main aim of reducing eosinophilic-driven exacerbations by the inhaled corticosteroid moiety.1 Findings from the TRIBUTE study2 showed a 15% overall reduction in exacerbations and no difference in pneumonia risk when comparing a triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium to a dual combination of indacaterol plus glycopyrronium in COPD.